Protective Immunity Using Recombinant Human IL-12 and Alum as Adjuvants in a Primate Model of Cutaneous Leishmaniasis
Open Access
- 15 October 1999
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (8) , 4481-4488
Abstract
Protection from cutaneous leishmaniasis, a chronic ulcerating skin lesion affecting millions, has been achieved historically using live virulent preparations of the parasite. Killed or recombinant Ags that could be safer as vaccines generally require an adjuvant for induction of a strong Th1 response in murine models. Murine rIL-12 as an adjuvant with soluble Leishmania Ag has been shown to protect susceptible mice. We used 48 rhesus macaques to assess the safety, immunogenicity, and efficacy of a vaccine combining heat-killed Leishmania amazonensis with human rIL-12 (rhIL-12) and alum (aluminum hydroxide gel) as adjuvants. The single s.c. vaccination was found to be safe and immunogenic, although a small transient s.c. nodule developed at the site. Groups receiving rhIL-12 had an augmented in vitro Ag-specific IFN-γ response after vaccination, as well as increased production of IgG. No increase in IL-4 or IL-10 was found in cell culture supernatants from either control or experimental groups. Delayed hypersensitivity reactions were not predictive of protection. Intradermal forehead challenge infection with 107 metacyclic L. amazonensis promastigotes at 4 wk demonstrated protective immunity in all 12 monkeys receiving 2 μg rhIL-12 with alum and Ag. Partial efficacy was seen with lower doses of rhIL-12 and in groups lacking either adjuvant. Thus, a single dose vaccine with killed Ag using rhIL-12 and alum as adjuvants was safe and fully effective in this primate model of cutaneous leishmaniasis. This study extends the murine data to primates, and provides a basis for further human trials.Keywords
This publication has 47 references indexed in Scilit:
- Vaccine for prophylaxis and immunotherapy, BrazilClinics in Dermatology, 1996
- Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteersClinics in Dermatology, 1996
- Genetically resistant mice lacking interleukin‐12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell responseEuropean Journal of Immunology, 1996
- Meetings on vaccine studies towards the control of leishmaniasisMemórias do Instituto Oswaldo Cruz, 1995
- The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania majorScience, 1994
- Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.Journal of Experimental Medicine, 1993
- Recombinant interleukin 12 cures mice infected with Leishmania major.Journal of Experimental Medicine, 1993
- Experiences with vaccines against cutaneous leishmaniasis: of men and miceParasitology, 1989
- Aluminium hydroxide granulomas: light and electron microscopic studies and X-ray microanalysisBritish Journal of Dermatology, 1982
- STUDIES ON ANTIBODY PRODUCTIONJournal of Experimental Medicine, 1955